PMVP News and Press, PMV Pharmaceuticals Inc. From 03/27/24

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients...

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) i n heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of th...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024 Ph...

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David Mack, Ph.D., President and Chief Executive Offic...

2024-01-18 16:57:20 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Ladenburg Thalmann starts PMV Pharmaceuticals at buy Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earning...

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from wor...

2024-01-05 16:10:58 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Ladenburg Thalmann starts PMV Pharmaceuticals at buy For further details see: PMV Pharmaceuticals names Michael Carulli as CFO

PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael Carulli promoted to Chief Financial Officer Robert Ticktin, General Counsel, will exp...

2023-12-28 16:12:39 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Financial information ...